Ab­b­Vie hatch­es plans for a ma­jor new R&D hub close to its part­ners in Bay Area's buzzy Oys­ter Point

Ab­b­Vie has signed on to be the first ten­ant of a mas­sive new re­search cen­ter in Oys­ter Point, join­ing a flock of bio­phar­ma peers that’s set up shop in the in­creas­ing­ly pop­u­lar South San Fran­cis­co neigh­bor­hood.

The North Chica­go, IL-based drug­mak­er — whose Stem­cen­tryx sub­sidiary has an op­er­a­tion in the area — is leas­ing al­most 480,000 square feet in the Gate­way of Pa­cif­ic, a 1.4 mil­lion square foot cam­pus un­der con­struc­tion by Bio­Med Re­al­ty. Ink­ing a deal for 10 years, Ab­b­Vie will oc­cu­py a 12-sto­ry tow­er in a space that could even­tu­al­ly hold 1,500 work­ers, the San Fran­cis­co Busi­ness Times re­port­ed.

The new fa­cil­i­ty will “rep­re­sent a Bay Area hub for Ab­b­Vie’s on­col­o­gy busi­ness,” which is cur­rent­ly spread be­tween three dis­tinct lo­ca­tions in the re­gion, Ab­b­Vie spokesper­son Ilke Limon­cu tells End­points News.

“This fu­ture fa­cil­i­ty will al­so fur­ther strength­en our pres­ence in the Bay Area and bring to­geth­er our cur­rent three sites to im­prove col­lab­o­ra­tion and help us grow Ab­b­Vie’s on­col­o­gy sci­ence, re­search, in­no­va­tion and pa­tient care am­bi­tions,” he writes in an email.

The new lo­ca­tion would make Ab­b­Vie a neigh­bor of Genen­tech’s Gate­way cam­pus, while plac­ing it just 10 min­utes away from mul­ti­ple part­ners at Cal­i­co, Cy­tomX and Alec­tor.

When Ab­b­Vie and Cal­i­co re­newed their mon­ster dis­cov­ery deal in June, each com­mit­ting $500 mil­lion more to their al­liance, the Google-backed an­ti-ag­ing biotech made the un­usu­al move to an­nounce that it’s built a team of 150-plus around an HQ base in South San Fran­cis­co, with plans to add more.

Big names and fledg­ling biotechs alike have tak­en a lik­ing to the R&D hub in San Fran­cis­co, with Oys­ter Point in par­tic­u­lar buzzing with new oc­cu­pants. Sang­amo un­veiled plans to build a new HQ right on a ma­ri­na late last year, while As­traZeneca is bring­ing staffers from var­i­ous biotechs it ac­quired to­geth­er at its Cove at Oys­ter Point site.

“The core of Ab­b­Vie’s ini­tia­tive is fo­cused on the tal­ent, in­no­va­tion and cul­ture in the Bay Area,” Di­no Per­az­zo, a rep­re­sen­ta­tive of Ab­b­vie from re­al es­tate bro­ker­age CBRE’s life sci­ence prac­tice, told the San Fran­cis­co Busi­ness Times. “Theirs is the first of what will like­ly be many phar­ma ini­tia­tives com­ing to the Bay Area in the near fu­ture.”

While the the first phase of Gate­way of Pa­cif­ic is ex­pect­ed to com­plete in 2019 — with 431,000 square feet in phase II space to come lat­er — Ab­b­Vie won’t be­gin to move in un­til 2021, when its cur­rent Cal­i­for­nia leas­es ex­pire, Limon­cu con­firms.


Im­age: GATE­WAY OF PA­CIF­IC

Jan Hatzius (Photographer: Christopher Goodney/Bloomberg via Getty Images)

When will it end? Gold­man econ­o­mist gives late-stage vac­cines a good shot at tar­get­ing 'large shares' of the US by mid-2021 — but the down­side is daunt­ing

It took decades for hepatitis B research to deliver a slate of late-stage candidates capable of reining the disease in.

With Covid-19, the same timeline has devoured all of 5 months. And the outcome will influence the lives of billions of people and a multitrillion-dollar world economy.

Count the economists at Goldman Sachs as optimistic that at least one of these leading vaccines will stay on this furiously accelerated pace and get over the regulatory goal line before the end of this year, with a shot at several more near-term OKs. That in turn should lead to the production of billions of doses of vaccines that can created herd immunity in the US by the middle of next year, with Europe following a few months later.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 86,400+ biopharma pros reading Endpoints daily — and it's free.

J&J gets a fresh OK for es­ke­t­a­mine, but is it re­al­ly the game-chang­er for de­pres­sion Trump keeps tweet­ing about?

Backed by an enthusiastic set of tweets from President Trump and a landmark OK for depression, J&J scooped up a new approval from the FDA for Spravato today. But this latest advance will likely bring fresh scrutiny to a drug that’s spurred some serious questions about the data, as well as the price.

First, the approval.

Regulators stamped their OK on the use of Spravato — developed as esketamine, a nasal spray version of the party drug Special K or ketamine — for patients suffering from major depressive disorder with acute suicidal ideation or behavior.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 86,400+ biopharma pros reading Endpoints daily — and it's free.

FDA hands Mor­phoSys and In­cyte a quick OK on their po­ten­tial block­buster CAR-T al­ter­na­tive

Nearly three years after okaying the CAR-Ts Yescarta and Kymriah, the FDA has approved a new CD19 therapy.

MorphoSys’ Monjuvi, or tafasitamab-cxix, was cleared Friday for use in refractory diffuse large B-cell lymphoma (DBLCL). The approval sets up both MorphoSys and their commercial partner Incyte to compete with Gilead and Novartis in the ultra-competitive indication, where similar trial results and far easier delivery could allow them to cut a fair share of the market.

So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo study

Before the coronavirus global emergency stole the R&D show in biopharma, the leaders in the race to develop new mRNA therapies had a big interest in determining if their tech could be used to create an effective cancer vaccine after all the first-gen tries had failed to impress. So perhaps it’s not surprising that an early cut of the data at frontrunner BioNTech went largely unnoticed.

Unless you were at Regeneron.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

CymaBay flash­es pos­i­tive re­sults from the tri­al they have to re­launch

Two weeks after the FDA lifted its clinical hold on their lead drug, CymaBay said it showed positive results in an aborted Phase III trial.

The drug, a small molecule known as seladelpar, had been in development for three different liver conditions before an independent review of a NASH study last year showed that it might actually be damaging patient’s liver cells. The FDA slapped a clinical hold across all three trials, only lifting it last month when an FDA review determined that the drug hadn’t caused liver damage.

Sev­en plucky di­ag­nos­tics com­pa­nies win a $249M round of con­tracts af­ter sur­viv­ing NI­H's Covid-19 'Shark Tank' com­pe­ti­tion

As US Covid-19 deaths creep past 150,000 and officials stress the importance of contact tracing, the NIH’s Rapid Acceleration of Diagnostics (RADx) program has inked contracts totaling $248.7 million to expand testing capabilities.

The seven contracts, which were chosen “Shark Tank”-style from a pool of 100 proposals, are part of an effort to bump daily testing capacity to 2% of the country’s population by late summer or fall. That would be about 6 million people per day, compared to the current 520,000 to 823,000 tests being administered daily.

Covid-19 roundup: Eli Lil­ly retro­fits RVs for first-of-its-kind an­ti­body tri­al with NIH; Am­gen, Ab­b­Vie, Take­da team on a drug

Eli Lilly and the NIH are about to start a first-of-its-kind trial that researchers and developers have talked about for months as a way of providing temporary immunity to the most at-risk populations.

Lilly announced this morning that it will start a 2,400-person trial with the National Institute for Allergy and Infectious Diseases to test whether its experimental Covid-19 neutralizing antibody can prevent people in nursing homes and assisted living facilities from developing the disease. The idea, known as passive immunity, is that rather than waiting on a vaccine to induce people to develop antibodies, doctors can give them lab-grown antibodies. Ideally, those antibodies will either attack the new SARS-CoV-2 infection, if the patient has recently been exposed, or persist in the blood for several weeks and prevent infection or disease for that period.

Im­mu­nic's lead MS drug hits pri­ma­ry and key sec­ondary end­points in PhII, but ques­tions re­main

Just a week after its lead program began enrolling patients in a study to treat Covid-19, Immunic Therapeutics is making more waves.

This time, the biotech is providing a glimpse at topline data from a Phase II trial studying the efficacy of vidofludimus calcium, or IMU-838, in relapsing-remitting multiple sclerosis patients. Taken orally, the candidate met its primary endpoint in reducing the cumulative number of combined unique active MRI lesions after 24 weeks for a 45 mg dose compared to a placebo, as well as a key secondary endpoint in such reductions for the 30 mg dose.

Sanofi un­der for­mal in­ves­ti­ga­tion for De­pakine al­le­ga­tions; Beam li­cens­es CAR-T tech from Ox­ford Bio­med­ica

Sanofi is facing a formal investigation on manslaughter charges, due to accusations that its epilepsy drug Depakine caused birth malfunctions and slow neurological development when taken during pregnancy.

The French pharma was formally charged in February, years after evidence surfaced that the drug, sodium valproate, posed neurodevelopmental risks. Sodium valproate first hit the market in 1967 for the treatment of epilepsy and bipolar disorder, and is currently prescribed in more than 100 countries.